Monte Rosa Therapeutics, Inc. GLUE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s cash & equivalents?
- Monte Rosa Therapeutics, Inc. (GLUE) reported cash & equivalents of $159.86M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s cash & equivalents increased by 103.6% year-over-year, from $78.53M to $159.86M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s cash & equivalents has grown at a 25.5% compound annual growth rate (CAGR), from $41.7M to $129.88M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.